2-amino-4,5-difluorobenzenesulfonamide | 1993-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-4,5-difluorobenzenesulfonamide
• CAS: 1993-10-8
• 化学式: C₆H₆F₂N₂O₂S
• 分子量: 208.189
• InChiKey: PQSIISBSDXDVLD-UHFFFAOYSA-N

物化性质

• 熔点：
  129-130 °C
• 沸点：
  398.0±52.0 °C(Predicted)
• 密度：
  1.612±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-amino-4,5-difluorobenzenesulfonamide 在 光气 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 丙酮 、 甲苯 为溶剂， 反应 6.0h， 生成 6,7-Difluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide
  参考文献：
  名称：

  3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-Dioxides as ATP-Sensitive Potassium Channel Openers:  Effect of 6,7-Disubstitution on Potency and Tissue Selectivity

  摘要：

  A series of 6,7-disubstituted 4H-1,2,4-benzothiadiazine 1,1-dioxides bearing a short alkylamino side chain in the 3-position were synthesized. These compounds were tested on rat pancreatic islets and on rat aorta rings. In vitro data indicated that in most cases substitution in the 6 and the 7 positions increased their activity as inhibitors of insulin secretion, while the myorelaxant potency of the drugs was maintained or enhanced according to the nature of the substituent in the 7-position. The presence of either chlorine or bromine atoms in the 6 and 7 positions did not improve the apparent selectivity of the drugs for the pancreatic tissue. By contrast, the introduction of one or two fluorine atoms, as well as the presence of a methoxy group in the 7-position, generated potent and selective inhibitors of insulin release. Radioisotopic and fluorimetric experiments performed with the most potent compound inhibiting insulin release (34, BPDZ 259, 6-chloro-7-fluoro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide) confirmed that the drug activated K-ATP channels. 34 was found to be one of the most potent and selective pancreatic potassium channel openers yet described.

  DOI：

  10.1021/jm0580050
• 作为产物：
  描述：

  2-amino-4,5-difluorobenzenesulfonyl chloride 在 ammonium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 生成 2-amino-4,5-difluorobenzenesulfonamide
  参考文献：
  名称：

  PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用它们的方法。

  公开号：

  US20180127370A1

文献信息

• Bis-(Sulfonylamino) Derivatives in Therapy 205
  申请人：Bylund Johan

  公开号：US20090163586A1

  公开（公告）日：2009-06-25

  The invention provides compounds of formula (I) wherein R 1 , R 3 , L 1 , L 2 , G 1 , G 2 , A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.

  该发明提供了式（I）的化合物 其中R 1 ，R 3 ，L 1 ，L 2 ，G 1 ，G 2 ，A和m如规范中定义的那样，以及其光学异构体，消旋体和互变异构体，以及其药学上可接受的盐；以及它们的制备方法，含有它们的药物组合物以及它们在治疗中的应用。这些化合物是微粒体前列腺素E合成酶-1的抑制剂。
• 1,2,4-benzothiadiazine derivatives, their preparation and use
  申请人：Novo Nordisk AIS

  公开号：US06242443B1

  公开（公告）日：2001-06-05

  1,2,4-Benzothiadiazine derivatives represented by formula wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

  1,2,4-苯并噻二嗪衍生物的化学式如下： 其中D，R1，R2，R3，R4，R5，R12，R13，R14，R15在描述中有定义，描述了其组成以及制备该化合物的方法。 这些化合物在治疗中枢神经系统、心血管系统、呼吸系统、消化系统和内分泌系统疾病方面具有用途。
• Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them
  申请人：FRANCOTTE Pierre

  公开号：US20100009974A1

  公开（公告）日：2010-01-14

  Compounds of formula (I): wherein: R Cy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group, R 1 , R 2 , R 3 and R 4 , which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

  式（I）的化合物：其中：RCy表示未取代或取代的环烷基或环烷基烷基，R1、R2、R3和R4，可以相同也可以不同，每个代表氢或卤素原子或硝基团；氰基；羟基；烷氧基；烷基；未取代或取代的氨基团；羧基；烷氧羰基；芳基氧羰基；未取代或取代的氨基羰基。含有这些化合物的药物产品，可用于治疗或预防通过AMPA受体调节剂可治疗的疾病。
• [EN] 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE<br/>[FR] DERIVES DE 1,2,4-BENZOTHIADIAZINE, LEUR PREPARATION ET LEUR UTILISATION
  申请人：NOVO NORDISK A/S

  公开号：WO1997049692A1

  公开（公告）日：1997-12-31

  (EN) 1,2,4-Benzothiadiazine derivatives represented by formula (I) wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.(FR) Dérivés de 1,2,4-benzothiadiazine représentés par la formule (I) dans laquelle D, R1, R2, R3, R4, R5, R12, R13, R14, R15 sont définis dans le descriptif, leurs compositions et procédés de préparation de ces composés. Ces composés sont utiles dans le traitement de maladies du système nerveux central, du système cardio-vasculaire, du système pulmonaire, du système gastro-intestinal et du système endocrinien.

  1,2,4-苯并噻二嗪衍生物的化学式为（I），其中D，R1，R2，R3，R4，R5，R12，R13，R14，R15在描述中有定义，描述了这些化合物的组成和制备方法。这些化合物在治疗中枢神经系统、心血管系统、肺部系统、胃肠系统和内分泌系统疾病中有用。
• Bis-(sulfonylamino) derivatives for use in therapy
  申请人：Bylund Johan

  公开号：US09145380B2

  公开（公告）日：2015-09-29

  The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.

  本发明提供了式（I）的化合物，其中R1、R3、L1、L2、G1、G2、A和m如规范中所定义，并提供其光学异构体、外消旋体和互变异构体，以及其药学上可接受的盐；以及制备它们的方法、包含它们的制药组合物和它们在治疗中的用途。这些化合物是微粒体前列腺素E合成酶-1的抑制剂。